FDA: Abbott issues safety notice for MitraClip Delivery System
Editor's Note
The Food and Drug Administration on February 29 announced a safety notice issued by Abbott (Abbott Park, Illinois) to reinforce the proper procedures used to operate and deploy its MitraClip Delivery System.
The company has received nine reports of device malfunction where the user was unable to separate the implantable clip from the delivery system.
MitraClip is used to perform percutaneous transcatheter mitral valve repair.
Posted 02/29/2016] AUDIENCE: Cardiology, Risk Manager, Surgery ISSUE: Abbott initiated a voluntary safety notice regarding the MitraClip Delivery System to reinforce the proper procedures used to operate and deploy the device. The company received a small number of reports involving MitraClip Delivery Systems where the user was unable to separate the implantable Clip from the delivery system.
Read More >>
Free Daily News
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery